Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

$30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Published 12/01/2024, 11:38
Updated 12/01/2024, 12:40
© Reuters.  $30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
EYPT
-
ADC
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Dyne Therapeutics

  • The Trade: Dyne Therapeutics, Inc. (NASDAQ: DYN) 10% owner Dirk Kersten acquired a total of 1,714,285 shares an average price of $17.50. To acquire these shares, it cost around $30 million.
  • What’s Happening: Dyne Therapeutics recently priced $300 million public offering of 17.15 million common stock at $17.50 per share.
  • What Dyne Therapeutics Does: Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases.
EyePoint Pharmaceuticals
  • The Trade: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 10% owner Cormorant Global Healthcare Master Fund LP acquired a total of 855,000 shares at an average price of $19.94. To acquire these shares, it cost around $17.05 million.
  • What’s Happening: EyePoint recently said first patient was dosed in Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema.
  • What EyePoint Pharmaceuticals Does: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases.
Don’t forget to check out our premarket coverage here

Agree Realty

  • The Trade: Agree Realty Corporation (NYSE: ADC) Director, Executive Chairman of Board Richard Agree bought a total of 10,500 shares at an average price of $62.57. To acquire these shares, it cost around $656,985.
  • What’s Happening: Mizuho recently maintained Agree Realty with a Neutral and raised the price target from $61 to $65.
  • What Agree Realty Does: Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-leading tenants.

Check This Out: Investor Sentiment Eases Following Inflation Data; Bank Earnings In Focus

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.